UBS’s Orexigen Therapeutics OREX Stock Holding History
Bought
Maintained
Sold
Other funds holding OREX
UBS's OREX Position: Q3 2014 in Review
UBS reduced its Orexigen Therapeutics (OREX) stake by 12% in Q3 2014, selling an estimated $90.3K and leaving 11,978 shares worth $510K. The position accounts for ﹤0.01% of the portfolio, ranked #4259.
UBS first reported a position in OREX in Q2 2013 and has held it in 6 quarters since. The position peaked at $999K in Q1 2014. 128 funds tracked by Wall St. Rank hold OREX as of Q3 2014.
- UBS held 11,978 shares of Orexigen Therapeutics worth $510K as of Q3 2014.
- UBS sold 1,682 Orexigen Therapeutics shares in Q3 2014, an estimated $90.3K.
- Orexigen Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4259 holding.
- UBS first reported a position in Orexigen Therapeutics in Q2 2013 and has held it in 6 quarters since.
- UBS's Orexigen Therapeutics position peaked at $999K in Q1 2014.
- 128 funds tracked by Wall St. Rank held Orexigen Therapeutics as of Q3 2014.
Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.